Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 MonthsAccelerated pathway: ...
VANCOUVER, BC / ACCESSWIRE / May 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiaries ...
Frontage Laboratories, Inc., a leading contract development and manufacturing organization (CDMO) announced that its new ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
CRISPR-Cas9 is one of the most commonly leveraged non-viral editing tools to engineer cells for therapeutics applications. It is a nuclease-based genome editing system which has seen exponential ...
The company said this new commitment to its facility in Germany goes hand in hand with its recently announced ReciPredict, an initiative intended to streamline the product development cycle. Recipharm ...
BASEL, Switzerland, June 7, 2023 /PRNewswire/ -- Cell and gene therapy (CGT) is a cutting-edge therapy that combats cancer by bolstering the immune system through stem cell infusions or modified ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...
In Jan 2013, Almac completed the doubling of their pharmaceutical development service capabilities with the opening of a new dedicated non-GMP facility together with 2 analytical laboratories at their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback